E. Schimmel

发表

Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.

Henk Huizenga, Peep F M Stalmeier, Julia J van Tol-Geerdink, 2008, International journal of radiation oncology, biology, physics.

P. Stalmeier, J. Leer, J. J. van Tol-Geerdink, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

B. Heijmen, S. Aluwini, L. Incrocci, 2015, The Lancet. Oncology.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

B. Heijmen, M. Dirkx, S. Aluwini, 2015, The Lancet. Oncology.

Projected return on investment of a corporate global health programme

S. Hejazi, E. Schimmel, S. Peik, 2019, BMC Public Health.

[The patient chooses for feasibility and effectiveness].

H. Huizenga, P. Stalmeier, W. V. van Daal, 2009, Nederlands tijdschrift voor geneeskunde.

Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.

E. Noordijk, R. Willemze, E. Schimmel, 2009, International journal of radiation oncology, biology, physics.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

B. Heijmen, S. Aluwini, L. Incrocci, 2016, The Lancet. Oncology.

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

F. V. van Leeuwen, J. Gietema, R. de Wit, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do prostate cancer patients want to choose their own radiation treatment?

Henk Huizenga, Peep F M Stalmeier, Julia J van Tol-Geerdink, 2006, International journal of radiation oncology, biology, physics.

Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.

H. Huizenga, P. Stalmeier, W. V. van Daal, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT.

H. Huizenga, P. Stalmeier, P. P. Pasker-De Jong, 2006, International journal of radiation oncology, biology, physics.

OC-0218 ACUTE TOXICITY OF THE RANDOMIZED PHASE III DUTCH HYPOFRACTIONATION TRIAL (HYPRO) FOR PROSTATE CANCER

W. Ghidey, M. Dirkx, S. Aluwini, 2012 .

Hypofractionation in glioblastoma multiforme.

D. González, M. Hulshof, D. Bosch, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

OC-0052: Late toxicity in the randomized phase III Dutch Hypofractionation Trial for prostate cancer patients (HYPRO)

W. Ghidey, M. Dirkx, S. Aluwini, 2013 .